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tent at the race finish, while the other was certified dead later 
in a local private hospital.
Previous medico-legal autopsy diagnoses after sport-
related deaths in our personal experience in Durban included 
cardiomyopathy, coronary artery disease, Marfan’s syndrome 
and ruptured cerebral berry aneurysms.  It is regrettable that 
autopsies were not performed in the above cases.  Whether 
they should have been considered natural or unnatural may 
be debatable, but postmortem examinations could have 
served to establish the cause/s and mechanism/s of death 
without need for speculation, and before considerations on 
their preventability.  Routine autopsy examinations in such 
instances would enlighten issues of familial/genetic study and 
counselling, scientific research into this area, and for ‘selective 
pre-competition screening’ in sport.
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Pre-analytical, analytical and post- 
analytical considerations in glucose 
point-of-care testing
To the Editor: Point-of-care (POC) blood glucose monitoring 
has become an accepted method to evaluate patients in the 
hospital setting. In most situations, the method is accurate with 
a short turnaround time, which expedites treatment decisions. 
The important issue to keep in mind is that any point of care 
test is subject to pre-analytical, analytical and post-analytical 
variability. 
A case in point: a neonate who presented with prolonged 
jaundice, liver dysfunction (elevated transaminase, 
coagulopathy), and renal tubular dysfunction (normal anion 
gap metabolic acidosis and glucosuria), was treated with 
insulin after POC glucose values were reported to be above 15 
mmol/l. When the patient’s condition deteriorated, the POC 
glucose results were correlated with the laboratory plasma 
glucose concentrations done on the Beckman LX, using a 
glucose oxidase ion selective electrode method. The laboratory 
values were consistently low (discrepant to POC values). The 
urine showed 4+ galactose and the red cells showed reduced 
galactose-1-phosphate uridyl transferase (GALT) activity. The 
patient was diagnosed with galactosaemia. 
POC blood glucose meters have evolved rapidly and 
new-generation meters can exclude many of the previously 
encountered pre-analytical problems including inadequate 
sample volume, improper application and timing, removal of 
excess blood and lockout function if controls are out of range. 
Variables that may influence the analytical process include 
the haematocrit, environmental temperature or humidity, 
hypoxia, high triglyceride concentrations, and inaccuracy 
at very high and very low concentrations.1 Method-specific 
interferences are also encountered, e.g. the POC device in this 
case (Roche Accu-Check Active) is a glucose dehydrogenase 
pyrroloquinolinequinone (GDH-PQQ)-based glucose 
measuring system. This system is not specific for glucose 
and may give false elevated glucose values in the presence 
of maltose, xylose or galactose (Accu-Check Active test strips 
package insert).  Post-analytical factors that influence the 
interpretation of the result are whether a plasma or serum 
value is reported and the unit in which the result is reported. 
Recently, an International Federation of Clinical Chemistry 
(IFCC) working group recommended that all meters must 
be harmonised to the concentration of glucose in plasma, 
irrespective of the type of sample used.1,2
When a POC device is used, the clinician should always 
familiarise himself with the test method and the influence 
of possible interferences on the method. Methods using 
glucose dehydrogenase with NAD as co-factor (GDH-NAD), 
hexokinase or glucose oxidase are specific for glucose and do 
not exhibit interference as a result of interfering sugars.3
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Hypertension: Holding on to your ACEs 
may be a good bet
To the Editor: The recently published South African 
Hypertension Guideline1 provides a comprehensive review 
of the causes and risks of abnormal blood pressure and 
of its treatment, but falls short of offering a cost-effective 
approach to managing the burden. Understanding the causes 
of hypertension, the morbidity associated with it, and the 
effective treatments are necessary, but not sufficient, conditions 
for a cost-effective programme.2,3 Also, adding to the debate, 
one has to look at this from another perspective.
In clinical practice, it is often assumed that angiotensin 
receptor blockers (ARBs) and angiotensin-converting enzyme 
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inhibitors (ACEIs) can be used interchangeably, except for the 
small proportion of patients who develop ACEI-associated 
cough. Few studies has compared these classes head to head, 
and none has shown superiority of ARBs over ACEIs. While 
this evidence indicates that ACEIs and ARBs have equal 
efficacy in trial settings, the relative effectiveness of these drug 
classes in real populations and more typical health care settings 
is unknown.4 Indeed, it has been concluded that the use of 
ARBs may even confer a risk of harm, specifically through 
their association with higher rates of myocardial infarction 
(MI). This has given rise to much concern, with many health 
care professionals and patients asking whether ARBs should be 
avoided.5
However, before plunging into a debate on the use of 
ACEIs and ARBs, the point of departure ought to be the South 
African Guideline Working Group 2006 consensus statement: 
‘Compared with ACEI, ARBs provide a more effective blockade 
of the renin-angiotensin system’.1 Furthermore, the statement 
reads: ‘The price of ARBs remains a negative factor until it falls 
or there is a generic equivalent’. And herein lies an important 
caveat.
In addition to the situation after an MI, several systematic 
reviews have concluded that ACEIs and ARBs do not differ 
in efficacy for reducing all-cause mortality or hospitalisations 
in patients with chronic heart failure or high-risk MI, 
suggesting that the use of ARBs should be reserved. Others 
have even observed that while ACEIs have been shown to 
reduce all-cause mortality, such effectiveness has not yet been 
demonstrated for ARBs. As more expensive niche drugs, ARBs 
are therefore important for patients who develop a side-effect 
such as the aforementioned cough, or rash or angioedema. 
A switch to an ARB is not indicated for side-effects such as 
hypotension, decline in renal function, or increase in serum 
potassium concentrations, as these are equally likely with ARB 
therapy. In the absence of any financial constraint, one could 
argue that ARBs – with equal efficacy and fewer side-effects 
– should be used for most or all patients; however, prescription 
drug costs remain a major concern throughout the health care 
system and must be taken into account in weighing up choices 
between drug classes.4
The findings of a recent population-based study confirm 
that there is equivalence in survival after MI between 
patients who receive ARBs versus ACEIs, and that there is 
some evidence for increasing overutilisation of ARBs, which 
may be inappropriate, given their substantially higher cost. 
Reduction of these opportunity costs is important from a policy 
perspective, and could be achieved without impairing patient 
safety or clinical outcomes.4
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